NASDAQ · THAR
Tharimmune, Inc.
$3.54+$0.22 (+6.63%)
Tharimmune, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.01% below the high.
Loading market information…
NASDAQ · ICU · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
SeaStar Medical Holding Corporation’s quoted price sits in the lower half of its reported 52-week range, 61.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
SeaStar Medical Holding Corporation’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.95. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow SeaStar Medical Holding Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $338.00K+69.0% vs estimate |
| Q1 2025 | May 14, 2025 | -$4.40+15.38% vs estimate | $293.00K+95.33% vs estimate |
|---|
| Q4 2024 | Mar 27, 2025 | -$9.00-1.12% vs estimate | $67.00K-55.33% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | -$11.00+2.65% vs estimate | $68.00K-9.33% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $8.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.54+$0.22 (+6.63%)
Tharimmune, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.01% below the high.
$20.80+$0.83 (+4.16%)
Apollomics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.48% below the high.
$0.77-$0.03 (-3.15%)
Leap Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.5% below the high.
$6.75-$0.44 (-6.12%)
Athira Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.26% below the high.
$0.56+$0.02 (+4.07%)
Citius Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.45% below the high.
$2.02+$0.02 (+1.0%)
BioLineRx Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.86% below the high.
$8.72-$0.03 (-0.29%)
Moleculin Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.23% below the high.
$0.73-$0.08 (-10.09%)
Ainos, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.21% below the high.
